trending Market Intelligence /marketintelligence/en/news-insights/trending/xm1lZ3HEqUc58ZLsvOQBXw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Actinium closes offering of common stock, warrants

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Actinium closes offering of common stock, warrants

Actinium Pharmaceuticals Inc. closed its underwritten public offering of 21.5 million common shares and warrants to buy 18,275,000 common shares at 75 cents per share and related warrant.

The warrants have an exercise price of $1.05 per share and have a term of exercise of five years.

Gross proceeds from the offering were about $16.1 million, before deducting underwriting discounts and commissions and other offering expenses payable by Actinium.

The company plans to use the net proceeds to fund clinical development of Iomab-B, Actimab-A, Actimab-M, its alpha particle technology platform and for general corporate purposes.

Oppenheimer & Co. Inc. acted as sole book-running manager for the offering. Maxim Group LLC and JonesTrading Institutional Services LLC acted as co-managers for the offering.